Semaglutide vs MGF (Mechano Growth Factor)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Full details →MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Side-by-Side Comparison
| Aspect | Semaglutide | MGF (Mechano Growth Factor) |
|---|---|---|
| Mechanism | Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control. | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. |
| Typical Dosage | Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary. | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. |
| Administration | Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects. | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. |
| Side Effects | Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions. | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. |
| Best For |